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ABSTRACT
The E2 proteins are transcription/replication factors
from papillomaviruses. Human papillomaviruses
(HPVs) can be broadly divided in two groups; low-
risk HPV subtypes cause benign warts while high-
risk HPVs give rise to cervical cancer. Although a
range of crystal structures of E2 DNA-binding
domains (DBD) from both high- and low-risk HPV
subtypes have been reported previously, structures
of E2 DBD:DNA complexes have only been available
for high-risk HPV18 and bovine papillomavirus
(BPV1). In the present study we report the unligan-
ded and DNA complex structures of the E2 DBD
from the low-risk HPV6. As in the previous E2–DNA
structures, complex formation results in consider-
able bending of the DNA, which is facilitated by
sequences with A:T-rich spacers that adopt a pre-
bent conformation. The low-risk HPV6 E2–DNA
complex differs from the earlier structures in that
minimal deformation of the protein accompanies
complex formation. Stopped-flow kinetic studies
confirm that both high- and low-risk E2 proteins
adapt their structures on binding to DNA, although
this is achieved more readily for HPV6 E2. It
therefore appears that the higher selectivity of the
HPV6 E2 protein may arise from its limited molecu-
lar adaptability, a property that might distinguish the
behaviour of E2 proteins from high- and low-risk
HPV subtypes.
INTRODUCTION
Human papillomaviruses (HPVs) are icosahedral DNA
tumour viruses that infect epithelial and squamous tissue
[reviewed in (1)]. Although there are >100 types of HPVs,
the viruses can be divided into two groups: high-risk types
such as HPV16 and HPV18 are associated with cancer and
low-risk types such as HPV6 which are the causative agent
of benign warts. The viral protein E2 is a transcription/
replication factor that regulates production of the viral
oncogene products E6 and E7 (2). High-risk HPVs often
integrate into the host genome during tumourigenesis and
this usually leads to disruption of the E2 gene and conco-
mitant loss of E6 and E7 regulation. E2 also plays roles in
viral genome replication and segregation by forming a com-
plex with the helicase E1 (3) and by binding to host mitotic
chromosomes (4).
The E2 protein is homodimeric, each monomer comprising
360 amino acids with a mass of 42 kDa. E2 consists of three
domains—the N-terminal transcription activation/replication
domain (TAD), a central hinge region and a C-terminal
DNA-binding domain (DBD). Although a crystal structure
of the whole E2 protein has not been reported, there are
several structures from different papillomaviruses of both
the N-terminal domain (5,6) and DBD (see below). The
N-terminal domain is 200 residues in length, forms a
dimer and is conserved throughout all HPV types. This
domain interacts with the helicase E1 and recruits this protein
to the viral origin of replication to facilitate viral genome
replication (3). The proline rich central hinge region has
90 amino acids but is poorly conserved throughout the E2
proteins. However, there is evidence that the central hinge
region plays more than just a structural role (2). The
C-terminal DBD is basic (isoelectric point ¼ 9.8 in the
case of HPV6 E2) and forms a dimer of mass 20.4 kDa.
We have reported previously the crystal structure of the
low-risk HPV6 E2 DBD in the absence of DNA [PDB code
1r8h (7)] confirming that the structure is highly similar to
other E2 DBDs [crystal structures of E2 DBDs have also
been reported for the high-risk HPV16 (8), HPV31 (9),
HPV18 (10) and the bovine virus BPV1 (11), including the
latter two in complex with their cognate DNA sequences
(10,11)]. HPV6 E2 DBD shares 56, 49, 50 and 33% sequence
identity, respectively, with each of these proteins. Solution-
based (NMR) structures have also been reported for BPV1
(12), HPV31 (13) and HPV16 E2 DBDs (14), including
most recently the latter in the presence of DNA (15). The
DBD dimer is formed around a central eight-stranded anti-
parallel b-barrel structure, with four strands donated from
each monomer. Each subunit contains a DNA-binding helix
that binds two successive major grooves of the DNA target
(10,11). Comparisons of the unliganded and complexed
forms of HPV18 and BPV1 E2 proteins show that quaternary
structural rearrangements within the E2 dimer accompany
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DNA binding (10,11). However, no structure has up till now
been reported for an E2 DBD from a low-risk HPV in
complex with DNA.
There are four E2-binding sites in the long control region
(LCR) of the HPV genome. The consensus sequence is
50-ACCgN4cGGT-30 (where upper case letters represent
bases absolutely required, lower case letters represent bases
that are preferred but not essential and N4 is the variable cen-
tral spacer region). The crystal structures of the E2–DNA
complexes (10,11) confirm that, whereas direct contacts are
made between E2 and the sequence-specific required bases,
there are no direct contacts to the central spacer. The E2
DBD from the low-risk HPV6 preferentially binds a consen-
sus sequence containing an A:T-rich central spacer region
(e.g. AATT). Although this property is also shared by E2
DBD from the high-risk HPV16, the latter will also bind to
sites with central spacers of sequence ACGT and CCGG,
but with a 10-fold reduction in affinity compared to the
1000-fold reduction in affinity for the HPV6 protein (7,10).
BPV1, on the other hand, appears to have no preference for
particular central spacer sequences (16).
DNA is intrinsically flexible; however, some DNA
sequences are more flexible than others. E2 DBD binding
to its DNA target sequence has been shown to lead to bending
of the DNA by up to 50 (10,11). This bending leads to
narrowing of the minor groove of the central spacer region.
HPV6 E2 DBD binds sequences containing A-tracts (4–6
consecutive A or T residues) which are intrinsically bent
(17). This intrinsic bending becomes more pronounced on
association with E2, leading to an even narrower minor
groove. It therefore appears that E2 DBD–DNA binding is
dependent not only on the conserved regions of the binding
site forming contacts with the DNA-binding helices, but
also on the conformation of the central spacer and inherent
degree of flexibility of the DNA sequence. A recent study
has shown that the binding of HPV16 E2 and BPV1 E2 to
sites with different spacer regions is sensitive to the presence
of cations that are presumed to stabilize bent DNA conforma-
tions by localizing within the narrowed minor groove (18). In
both the BPV1 and HPV18 DNA complexes, deformation
(especially in the placement of the DNA-binding helices) of
the protein also accompanies binding, and partial ordering
of the b2–b3 loop is observed in the BPV1:DNA complex.
These observations are supported by the NMR studies in
which the recognition helix is noted to be well defined but
prone to rapid amide-exchange, and the b2–b3 consistently
disordered in the absence of DNA ligand (12). The present
consensus is therefore that association of E2 with its target
DNA sequence is achieved through deformation of both the
protein and DNA structures.
Here we present crystal structures of the low-risk HPV6 E2
DBD in the absence of DNA, and bound to 16 and 18 bp
forms of its cognate DNA target (50-CAACCGAATTCGGT-
TG-30 and 50-GCAACCGAATTCGGTTGC-30, respectively),
spacer sequence shown in bold. These structures permit a
comparison of the crystal conformation of HPV6 E2 DBD
both in the presence and absence of its target DNA. Addition-
ally, using stopped-flow fluorescence techniques we have
monitored the binding of this protein–ligand pair in solution.
Both of these methods confirm the HPV6 E2 DBD protein
undergoes a small conformational rearrangement on DNA
binding, as has been noted previously for the BPV1,
HPV16 and HPV18 E2 proteins. However, the crystal
structures indicate that the extent of this structural change
is limited for HPV6 E2 implying that the low-risk HPV6
E2 protein may have limited adaptability and therefore be
more selective in its association with DNA.
MATERIALS AND METHODS
Protein purification
The HPV6 and HPV16 E2 DBD proteins were expressed and
purified as described previously (7). In outline, HPV6 or
HPV16 E2 DBD was expressed in Escherichia coli XL1-
blue cells. An SP-sepharose column was used to purify
HPV6 E2 DBD from the cell lysate. The eluted protein was
then further fractionated on a MonoS 5/5 column and the pro-
tein was then dialysed into 20 mM Tris, pH 8.5, 100 mM
NaCl and 10 mM DTT. For HPV6 E2 the fractions of the
Mono S 5/5 column were dialysed into fresh column buffer
and loaded onto a Heparin column. The protein was eluted
off the column with a 0–100% 1.5 M NaCl gradient. The
E2 protein fractions were dialysed into either the crystalliza-
tion buffer (20 mM Tris, pH 8.5, 10 mM DTT and 100 mM
NaCl) for structural studies or into 50 mM sodium phosphate,
150 mM NaCl and 2 mM DTT for stopped-flow studies.
DNA purification
Oligonucleotides (10 mmol batches) were purchased from
MWG-Biotech (Ebersberg, Germany). Samples of the
18mer were suspended in 25 mM Tris, pH 7.5, 100 mM
NaCl and 0.02% sodium azide to a final concentration of
1 mM, and annealed by heating to 95C for 2 min followed
by slow cooling over 16 h to form duplex DNA.
The double-stranded DNA (dsDNA) was purified using a
1 ml ResourceQ column (Amersham Pharmacia) equilibrated
in 25 mM Tris, pH 7.5 and 100 mM NaCl and eluted with a
0–700 mM NaCl gradient. Fractions containing the oligo-
nucleotide were buffer exchanged and concentrated using a
3K Centricon concentrator (Millipore, Billerica, USA), the
final DNA concentration being determined by A260 readings,
assuming that dsDNA at a concentration of 50 mg/ml has an
absorbance of A260 ¼ 1 (19).
The 16mer oligonucleotide was purified using a similar
procedure except that before annealing it was initially frac-
tionated in its single-stranded form using a 1 ml Resource
Q column (Amersham Pharmacia) equilibrated in 10 mM
NaOH and eluted using a 10 mM to 1 M NaCl gradient.
Crystallization of E2 DBD/S
The alternative crystal form of HPV6 E2 DBD was fortu-
itously obtained in an attempt to co-crystallize E2 DBD
with oligonucleotide. E2 DBD at a concentration of 2.5 mg/ml
in 1· phosphate-buffered saline, 0.1% b-mercaptoethanol
and 0.02% sodium azide was mixed at a 1:1.2 molar ratio
with dsDNA in 25 mM Tris, pH7.4, 100 mM NaCl and
1 mM MgCl2. After 20 min the complex was concentrated
to 3 mg/ml in a 3 kDa Centricon concentrator (Millipore).
Crystals—later found to only contain the protein—grew
after 6 days at 18C in 1–1.5 M ammonium sulphate,
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0.1 M Tris, pH 7.5–8.5 and 12% v/v glycerol. A solution of
1.1 M ammonium sulphate, 0.08 M Tris, pH 8.0 and 20% v/v
glycerol was used as a cryoprotectant. X-ray diffraction data
were collected at Daresbury SRS synchrotron on beamline
PX 10.1 (l ¼ 1.284 A˚) to a resolution of 2.3 A˚. Data were
processed using HKL2000 (20) in the space group C2 with
a unit cell of a ¼ 97.7, b ¼ 106.9, c ¼ 74.9, a ¼ g ¼ 90,
b ¼ 121.7. The structure was solved by molecular replace-
ment using PHASER (21) and the coordinates of the previ-
ously solved structure of HPV6 E2 DBD (PDB code 1r8h)
as a search model. All model building was performed in
COOT (22) and refinement in Refmac5 (23). The X-ray data
processing and model refinement statistics are shown in
Table 1.
Co-Crystallization of E2 DBD and its DNA target
E2 DBD at a concentration of 7 mg/ml in 20 mM Tris,
pH 8.5, 100 mM NaCl and 10 mM DTT was incubated in a
1:1.2 molar ratio with dsDNA of the required length for
20 min at room temperature. Crystals of the E2 DBD–
18mer complex grew in 0.1 M sodium chloride, 0.1 M
HEPES, pH 7.4–7.6, 1.4–1.8 M ammonium sulphate and
10 mM DTT after 4–5 days. A solution of 20% glycerol,
0.08 M sodium chloride, 0.08 M HEPES, 1.3 M ammonium
sulphate and 8 mM DTT was used as a cryoprotectant.
Crystals of E2 DBD–16mer complex grew in 1.4–1.6 M
tri-Sodium citrate dehydrate pH 6.5 and 10 mM DTT after
4–5 days. A solution of 10% glycerol in 1.4 M sodium citrate
and 9 mM DTT was used as a cryoprotectant. As DNA bind-
ing to E2 DBD requires a reducing environment the crystals
were grown in 10 mM DTT and frozen in liquid nitrogen
once they had reached a suitable size for data collection.
X-ray diffraction data were collected at Daresbury SRS on
beamline PX 14.1 (l ¼ 1.488 A˚, 18mer co-crystal) and
using a Bruker Proteum R (l ¼ 1.548 A˚, 16mer co-crystal).
Both co-crystal datasets were processed using HKL2000 (20)
in space group P61. The structure was solved by molecular
replacement using PHASER (21) and the coordinates of
HPV18 E2 DBD bound to its DNA target as a search
model [PDB code 1jj4, (10)]. Model building was performed
in COOT (22) and QUANTA and refinement in Refmac5
(23). The X-ray data processing and model refinement
statistics are shown in Table 1.
Solution-binding studies
In both the HPV6 E2 and HPV16 DBD E2 sequences there
are two conserved tryptophans, at positions 317 and 319.
These are located close to the core of the dimer and immedia-
tely below the DNA-binding site. Previous studies (24) on
HPV16 E2 have indicated a change in fluorescence of these
tryptophans can be detected on DNA complex formation. In
this study we measured DNA–E2 DBD complex formation in
solution for both HPV6 E2 DBD and HPV16 E2 DBD by
monitoring tryptophan fluorescence emission at 340 nm
following excitation at 285 nm under stopped-flow conditions
using an Applied Photophysics SpectraKinetic Monochro-
mator and Workstation. The protein dimer concentration
was kept constant at 0.2, 0.05 or 0.5 mM in 50 mM sodium
phosphate, 150 mM NaCl and 2 mM DTT. The DNA concen-
tration was varied in integral steps from 0.5- to 15-fold molar
excess of the protein concentration. The stopped-flow cham-
ber was kept at a constant temperature of 25C, and data col-
lected at intervals from 500 to 50 ms with the filter set to 1%
of the timescale and a voltage offset of 4 V. Approximately
25 sets of data were measured for each concentration of
DNA and then averaged using Grafit 3 software (Erithacus
Software, Staines, UK). The initial data were fitted to a
double exponential curve with offset:
y ¼ A1*

1  eðk1*tÞ

þ A2*

1  eðk2*tÞ

þ c‚
where A1 ¼ Amplitude 1, A2 ¼ Amplitude 2, k1 ¼ fast rate,
k2 ¼ slow rate and c ¼ Offset.
The rates obtained were then plotted against the DNA con-
centration and fitted to a straight line from which the forward
(gradient) and reverse (y-intercept) rates were derived. These
data were combined with the published binding constants for
HPV6 E2 and HPV16 E2 (7) to the oligonucleotide to derive
an overall model for association.
RESULTS AND DISCUSSION
Three structures of the E2 DBD from the low-risk HPV type
6a (HPV6 E2 DBD) have been solved in this study. One is an
unliganded (no DNA) structure that contains disulphide
bonds between the DNA-binding helices (HPV6 E2 DBD-S).
The remaining two are structures of HPV6 E2 DBD bound to
Table 1. Summary of X-ray diffraction data collection and refinement statistics
E2 DBD/S E2 DBD–18mer E2 DBD–16mer
Resolution range (A˚) 17–2.3 (2.32–2.3) 50.0–3.1 (3.2–3.1) 50.0–3.2 (3.3–3.2)
Space group C2 P61 P61
Unit cell a ¼ 97.7, b ¼ 106.9, c ¼ 74.9,
a ¼ g ¼ 90, b ¼ 121.7o
a ¼ 73.4, b ¼ 73.4, c ¼ 109.2,
a ¼ b ¼ 90, g ¼ 120
a ¼ 75.2, b ¼ 75.2, c ¼ 97.4,
a ¼ b ¼ 90, g ¼ 120
Unique reflections 28323 (2402) 6087 (610) 5168 (570)
Redundancy 8.2 (7.0) 7.6 (7.1) 22.5 (22.5)
Completeness (%) 97.4 (82.7) 99.9 (99.8) 99.8 (100.0)
I/s 37.3 (5.5) 17.9 (4.2) 19.8 (5.2)
Rmerge (%) 5.3 (21.7) 11.8 (35.1) 13.8 (38.7)
Refined model
Rfree 25.4 28.8 29.7
Rfactor 18.5 20.3 18.9
r.m.s.d. bond length (A˚) 0.02 0.02 0.02
r.m.s.d. bond angle (o) 2.0 2.3 2.3
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the dsDNA target sequences 50-GCAACCGAATT-
CGGTTGC-30 (18mer) and 50-CAACCGAATTCGGTTG-30
(16mer). We have shown previously that HPV6 E2 DBD
has an affinity of 2.0 ± 0.9 nM for a slightly extended
(20mer) form of this DNA sequence (7).
The structure of HPV6 E2 DBD in the absence of DNA
We have reported previously the structure of unliganded
HPV6 E2 DBD and shown that, like previous structures of
E2 DBD proteins, this DBD of E2 forms a homodimer built
from a central eight-stranded antiparallel b-barrel and four
a-helices [as seen for HPV6 E2 in its complex with DNA
in Figure 1]. Four strands of the b-barrel are donated from
each monomer, and each monomer contains two a-helices,
one of which inserts into the DNA major groove and will
be referred to as the DNA recognition helix. The secondary
structure elements occur in the order b1–a1–b2–b3–a2–b4.
a1 is the DNA recognition helix and the dimer interface is
between the b2 and b4 strands of each monomer.
A prominent feature of the novel crystal form of the unli-
ganded E2 DBD crystal structure solved in this study (E2
DBD-S) is the presence of disulphide bonds between the
DNA-binding helices of neighbouring molecules in the crys-
tal lattice. These stabilizing disulphide bonds are made across
the crystallographic 2-fold symmetry axis and form between
Cys295 in one helix and Cys298 from the helix in the neigh-
bouring molecule. Both of these cysteine residues are shown
to form close associations with the DNA chain in the DNA
complex structures (see below). Equivalent disulphide
bonds are also present in the structure of unliganded BPV1
E2 DBD (11). Oxidation of these cysteine residues to form
disulphide bonds would prevent the binding of DNA to the
protein dimer. It is possible that oxidation of the cysteine
residues acts as a mechanism to regulate the activity of the
E2 protein, ensuring that the protein is only active in reducing
environments such as within the cell nucleus. Previous stud-
ies have shown that E2 proteins are sensitive to the redox
environment both in vivo and in vitro (25). Redox regulation
of many other RNA-binding and DNA-binding proteins has
also been described in the literature.
E2 DBD-S crystallized in the space group C2 whereas the
previous unliganded HPV6 E2 structure was determined in
the space group P61 (7). Despite differences in the molecular
packing between these crystal classes, and changes in the
crystal contacts made by residues from the recognition
helix including the formation of the intermolecular disulphide
bond, there is no significant change in the quaternary struc-
ture of HPV6 E2 DBD between these structures (average
r.m.s.d. 0.6 A˚ when dimers of apo DBD and apo DBD-S
are compared based on 173 equivalent Ca atoms; the same
value is obtained when comparing any three of the dimers
from within each of the respective asymmetric units with
one another). As the DNA-binding helices are central to
E2:DNA complex formation, Hegde et al. (11) have
compared E2 structures previously by overlaying the helix
from one subunit, then using the relative displacement of
the DNA-binding helix on the adjacent, non-superimposed
subunit as a measure of conformational change. Using this
criterion, the mean displacement of the non-superimposed
recognition helix between the two HPV6 E2 unliganded
structures is 0.9 ± 0.3 A˚ (based on 12 equivalent Ca atoms
for the three copies of dimer in the asymmetric unit;
Table 2). As this helix is also the site of the disulphide forma-
tion, this small displacement is not surprising and but of
limited significance given the variation between each of the
dimers in the respective asymmetric unit cells (0.6 A˚) and
the resolution of these structures (1.9 and 2.3 A˚,
respectively). These data suggest that the crystal contacts
made by the helix (in this case including a covalent disul-
phide bond) do not overtly influence its placement. A similar
finding has been reported previously for the unliganded
BPV1E2 DBD, where the structure in a range of different
crystal lattices has been found to be essentially identical
[0.4 A˚ r.m.s.d. (11)]. Although the possibility always needs
to be considered that crystal lattices may trap proteins in
non-minimum energy conformations, this does not appear
to be the case for E2 DBD for which highly similar structures
have been observed in many different crystal lattices.
In contrast to all other reported structures of unliganded E2
DBDs, in both of these unliganded structures for HPV6
E2 DBD the b2–b3 loop is ordered. All other published E2
DBD structures have disordered b2–b3 loops in the DNA
free state (8,10–14). This loop in HPV6 E2 DBD-S is loosely
ordered (residues 323–328 are modelled at 50% occupancy in
the electron density), makes only weak, water-mediated con-
tacts in both crystal lattices and yet adopts a similar confor-
mation in both unliganded structures, and in the HPV
E2:DNA complex (Figure 2, described below). As has been
noted previously (7), the HPV 6 b2/b3 loop conformation
appears to be maintained primarily through the inclusion of
prolines at positions 322 and 325, and it seems likely that
the burial of the large hydrophobic tryptophan side chains
at positions 317 and 319 at the base of the loop may also sta-
bilize its conformation. Although the equivalent loop is not
ordered in previous E2 DBD:DNA complexes, a recent muta-
genesis study of HPV16 E2 DBD suggested residues Lys-325
Figure 1. The E2 DBD of HPV6a bound to its DNA target (18 bp in length).
The secondary structure elements are labelled and the AATT central spacer
sequence is boxed. The N- and C-termini of the protein chains are labelled N
and C, respectively, and 30 and 50 termini of the DNA labelled accordingly.
Figures 1, 2 and 4 were prepared with PyMol [www.pymol.org (37)].
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and Lys-327 in this loop participate in coulombic interactions
with the backbone phosphates of the DNA (26).
HPV6 E2 DBD bound to its DNA target sequence
In this study the crystal structures of HPV6 E2 DBD bound to
18mer and 16mer dsDNA have been solved. Both of these
structures are identical, except for the area where neighbour-
ing DNA helices are in contact with each other to form an
extended helix through the crystal. In the 18mer structure
symmetry related DNA helices are slightly staggered,
whereas in the 16mer structure the DNA helix is continuous
throughout the crystal. This latter complex was prepared after
solution and inspection of the 18mer complex, which sug-
gested that a shorter segment of DNA could be more readily
incorporated within the crystal lattice leading to a more
ordered crystal.
As has been described previously for the BPV1 and HPV18
E2:DNA complexes, the DNA recognition helices of the
HPV6 E2 DBD dimer bind to two successive major grooves
of the target DNA sequence (Figure 1). Protein–DNA con-
tacts are limited to the conserved regions of the target
sequence (Figures 1 and 3), and no direct contacts are
made with the central spacer of the DNA sequence. In
the E2–DNA complex, the DNA is seen to wrap around the
protein with a global bend angle of 24–28 (Table 3).
The length of the DNA may also influence the bend angle
as the 18mer bound to HPV6 E2 DBD has a slightly greater
bend angle (28) than the 16mer (24), although this is
unlikely to be significant given the resolution of the
structures.
Direct DNA contacts are made between eight amino acid
side chains in each recognition helix and to backbone phos-
phate or base atoms of the DNA. Most of these amino
acids are highly conserved throughout the papillomavirus
family. Owing to the limited resolution of the diffraction
data (3 A˚) water-mediated protein–DNA interactions can-
not be reliably assessed. Although solvent molecules are
believed to play an important role in E2 DBD–DNA binding
[e.g. see (15)], water molecules have only been conserva-
tively included in these crystal structures (12 in the 16mer
complex, 19 in the 18mer complex). For this description,
the DNA base numbering of the 18mer structure will be
used (with numbers in brackets referring to their position
from the centre of the 50–30oligonucleotide) and is shown in
Figure 3.
Table 2. The global bend angles and mean displacements of DNA-binding helices of various E2 DBD–DNA complexes
Protein DNA sequence PDB Code Global
benda (o)
Minor groove
width (A˚)b
pI of DNA
binding helices
HPV6 E2 DBD (16mer) 50-CAACCGAATTCGGTTG-30 2AYB 24 2.8 9.3
HPV6 E2 DBD (18mer) 50-GCAACCGAATTCGGTTGC-30 2AYG 28 2.8 9.3
HPV18 E2 DBD 50-CAACCGAATTCGGTTG-30 1JJ4 43 2.7 11.0
HPV18 E2 DBD 50-CAACCGACGTCGGTTG-30 Not deposited. Ref. (30) 49 2.7 11.0
BPV1 E2 DBD 50-CCGACCGAATTCGGTCG-30 R. S. Hegde, personal
communication
47 4.0 10.5
BPV1 E2 DBD 50-CCGACCGACGTCGGTCG-30 2BOP 51 4.0 10.5
None 50-ACCGAATTCGGT-30 1ILC 8.1 3.4 —
None 50-ACCGACGTCGGT-30 423D 0.4 6.1 —
The minimal minor groove widths [calculated as described in (17)] of the DNA duplex, the pI of the relevant DNA-binding helices and their displacements between
unliganded and DNA-complexed forms are shown. The global bend angles for HPV6 E2 were calculated in Madbend (33) and the remainder are as reported in (10).
aGlobal bend angles for HPV18 and BPV1complexes are from (10) or (30). Those for HPV6 complexes were calculated using Madbend (33), which gave similar
values for HPV18 and BPV1 to those previously reported.
bCalculated as closest distance between equivalent phosphate groups from opposing base pairs, less two times the atomic radius of a phosphorous atom.
Figure 2. Electron density for the b2–b3 loop and surrounding regions, including the bound DNA. The electron density map shown is calculated from 2Fo–Fc
coefficients, and is contoured at 2s. The residues in the b2– b3 loop (323–328) are seen to the upper right projecting away from the DNA, a segment of one
strand of which is shown below and numbered as in the schematic representation in Figure 3.
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Starting from the 50 end of the oligonucleotide (Figure 3)
the Arg302 guanidinium group forms charged hydrogen
bonds with the backbone phosphate of Cyt2 (+8) and a bifur-
cated interaction with both the base and phosphate group of
Ade3 (+7). The phosphate group of Ade3 (+7) also interacts
with the side chain of Thr353. Further along the oligonu-
cleotide chain, the base of Cyt5 (+5) is hydrogen bonded to
the side chain of Asn294. Consistent with the HPV18 E2
structure, there are then no direct contacts made between
the protein and DNA in the stretch from Cyt6 (+4) through
to Thy10 (1) inclusive (a region that incorporates the
AATT cognate sequence).
Contacts resume at Cyt12 (3), where the phosphate back-
bone makes a series of charged bonds with both the side
chain and main chain of Thr316, and Arg300 side chain.
This latter side chain also contacts the phosphate group of
Gua13 (4), which in turn is also bonded to the Lys297
side chain. The base of Gua14 is in van der Waals contact
(3.2 A˚) with the Tyr301 side chain, from which the hydroxyl
group also forms a hydrogen bond with the Lys297 side chain
amine group. The remainder of the nucleotides in the chain is
projected away from the protein surface. As the structure is
2-fold symmetric, most of these contacts are replicated on
the reverse (30–50) strand. No contacts are made between
the DNA and residues in the ordered b2–b3 loop.
HPV E2 DBD has two cysteine residues: Cys298 and
Cys295. These residues form disulphide bonds in the unli-
ganded E2 DBD-S structure, but have been suggested previ-
ously to be important for DNA binding (11,25). Neither of
these amino acids make direct contact with the DNA in the
HPV6 E2 DBD:DNA complex. However, Cys298 lies close
(4 A˚) to the bases from Ade3 (+7), Ade4 (+6), Cyt5 (+5)
and Gua14 (30–50 strand) and Cys295 is a similar distance
from the phosphate group of Ade3 (+8). In all cases
water-mediated contacts may be feasible.
A comparison of the unliganded HPV6 E2 DBD structures
with those incorporated within the DNA complexes shows
that only three of the residues in the DNA-binding helices
significantly change conformation on complex formation:
Lys297, Tyr301 and Arg302. These are surface-exposed
amino acids that exchange crystal contacts in the apo
structures for contacts with DNA in the complexes. Both
Lys297 and Tyr301 are required to move in order to prevent
steric clashes with the DNA, and both adopt alternative con-
formations that enable the formation of effective hydrogen
bonds with the DNA. Arg302 also alters its conformation
so that the side chain is closer to the DNA and improved
contacts can therefore be made. Both Tyr301 and Arg302
are in the vicinity of the ±7 bases, noted previously to form
an extension to the E2 consensus-binding site (7,27). Binding
data have indicated previously that A:T is preferred at
the 7:+7 sites, respectively. In this crystal structure the
Arg302 makes direct contacts with both the base and back-
bone phosphate group in the +7 position, explaining the
base preference noted in this extended binding site
region. A similar observation has been noted in the crystal
structure of the HPV18 E2:DNA complex (Arg 305 in
HPV18 E2) (10).
The majority of the DNA-binding residues are conserved
between all E2 DBD domains; however, there are some
differences. Asp295, Arg296 and Ser355 of HPV18 E2
Table 3. Displacement of recognition helices on DNA binding
E2 Resolution of structures
(complex/apo) (A˚)
Mean displacement of
recognition helix (A˚)
HPV18 (AATT) 2.3/1.9 3.5 ± 0.2
BPV1 (AATT) 2.3/2.5 2.6 ± 0.2
BPV1 (AGCT) 1.7/2.5 2.8 ± 0.5
HPV16 (NMR) 6.2 ± 0.7
HPV6 (AATT, 16mer) 3.2/1.9 1.9 ± 0.1
HPV6 (AATT, 16mer
versus 18mer)
3.2/3.1 1.3 ± 0.2
HPV6 apo versus
HPV6-S apo
1.9/2.3 1.2 ± 0.1
Displacements were calculated by overlaying the DNA-binding helix Ca’s
of one subunit (residues 293–304 in HPV18 and HPV6, 325–346 in BPV,
and 11–22 in HPV16) of the unliganded and DNA-complexed crystal struc-
tures, then measuring the mean displacement of the equivalent 12 Ca atoms of
the same helix from the other subunit. For each pair the mean displacements of
the helices used for the overlay were <0.5 A˚. The errors were estimated as the
standard deviations of the mean.
Figure 3. Schematic representation showing the contacts between the DNA-
binding helices of HPV6 E2 DBD and the 18 bp DNA target. The central
spacer is highlighted in bold. Each of the bases of the conserved region either
side of the central spacer have contacts with the DNA-binding helices. Red
arrows represent bonding to backbone phosphate atoms, black arrows
represent bonding to the bases. Thr353, Ser293 and Glu292 are highlighted
in green as these contacts are unique to HPV6 E2 DBD. For simplicity, each
amino is shown only once.
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DBD are replaced by Glu292, Ser293 and Thr353, respec-
tively, in HPV6 E2 DBD. The latter two interact directly
with the DNA backbone; and Glu292 does not interact with
the crystal structure but is sufficiently close to possibly estab-
lish a water-mediated contact. Arg307 of HPV18 E2 DBD
directly contacts the DNA backbone; however, this contact
is lost in HPV6 E2 DBD as this residue is Asn304 which is
too short to directly reach the DNA although it may do so
via a water molecule. Phe343 of BPV1 E2 DBD is replaced
by Tyr301 in HPV6 E2 DBD; both form van der Waals
contacts with the DNA. The interactions between DNA and
residues Glu292, Ser293 and Thr353 in HPV6 E2 DBD are
not present in the BPV1 E2:DNA complex as these positions
are occupied by Thr334, Ala335 and Gly398, respectively.
The solvent-accessible surface area [calculated with
Areaimol (28)] buried within the 16mer and 18mer comple-
xes is 1260 and 1374 A˚2, respectively. This is very similar
to the buried surface in the HPV18E2:AATT complex
(1223 A˚2) but less than in the BPV1:AATT complex
(1515 A˚2). The similarity to the HPV18 E2 complex is con-
sistent with the comparable binding affinities reported for E2
proteins from both high- and low-risk viruses.
The effect of DNA binding on the HPV6 E2 DBD
conformation
It has been noted previously that formation of the E2
DBD:DNA complex results in deformation of both the pro-
tein and DNA structures (10,11). Hegde et al. (11) noted
that changes in the BPV1 E2 protein structure equate to
small rearrangements of the secondary structure elements
rather than overall gross structural changes. As the DNA
recognition helices are critical to the interaction of E2 with
its target DNA, changes in the relative orientation of these
helices have been used as a measure of the deformation the
protein undergoes on complex formation. Hence, for BPV1
E2, monomers in the free and complexed forms can be read-
ily superimposed (r.m.s.d. of 0.55 A˚ for backbone atoms).
However, if one of the DNA recognition helices (a1) from
the free and complexed subunits is overlaid, the equivalent
helix from the non-superimposed subunits is seen to be
displaced by up to 3.5 A˚ (11). In Figure 4, we show similar
overlays for the BPV1, HPV18, HPV16 and HPV6 E2 DBDs.
In each of these cases, structural data are available both for
the unliganded form of the E2 DBD protein, and for the
same protein in complex with its cognate DNA sequence.
For these pairs of structures, we have overlaid one subunit
using the positions of 12 Ca atoms from the a1 helix
(Figure 4) and then measured the mean displacement for
the same Ca positions from the equivalent helix from the
non-superimposed subunit. The results are summarized in
Table 2.
Both from the figure and these data, it is evident that
HPV18 E2 undergoes a substantial rearrangement on com-
plex formation. The extent of this distortion is reduced for
BPV1 E2, and smallest for HPV6 E2. In each case the
changes are most prominent in the surface features such as
the a1 and a2 helices, there being minimal movement in
the residues forming the dimer interface [as reported for
BPV1 (11)]. Given the varying resolutions of the crystal
structures used for this analysis, some caution is warranted
in these interpretations. Nonetheless, the a1 recognition
helix is a prominent segment of secondary structure in the
E2 DBD, and is consistently well defined in all of the crystal
and NMR structures. Such elements are usually reliably
placed even in medium resolution crystal structures. The mul-
tiple copies of the HPV6 E2 dimer within the two apo crystal
structures provide an internal comparison whereby variations
in displacement between the various dimers are consistently
0.6 ± 0.1 A˚. This small variation comprises both inherent
flexibility of the helix relative to the domain fold and errors
within the crystal structures. Similarly, the availability of
both a 16mer and 18mer structure for the HPV6 E2
DBD:DNA complex, both of restricted resolution (3 A˚),
allows a comparison of the helix displacement between
these structures (1.3 ± 0.2 A˚) reflecting both the small change
in DNA bending angle between these structures (4) and the
increased error associated with the diminished resolution. The
displacements measured between all pairs of liganded/
unliganded E2 DBDs exceed these values.
The crystal structure of the unliganded E2 DBD from
another high-risk papillomavirus, HPV16, is also available
(8) as is its solution structure (14), and very recently its solu-
tion structure in the presence of cognate DNA has also been
reported (15). The deposited coordinates have been included
in our analysis (Table 2) and suggest there is a considerable
shift in the relative placement of the recognition helices asso-
ciated with DNA binding for HPV16 E2 (Figure 4d).
Figure 4. Rearrangement of the DNA-binding helices on DNA complex
formation with (a) HPV6 E2 DBD, (b) HPV18 E2 DBD, (c) BPV1 E2 and
(d) HPV16 E2 DBD. In each case E2 DBD is shown as a ribbon trace with the
unliganded structure in dark grey overlaid on the structure of the DNA
complex (light grey) to maximize the fit of the a1 helix from the left subunit.
The resulting relative positions of the a1 helix from the right subunit are
shown in red for the unliganded structure, and blue for the DNA complex
structure. For HPV6, HPV18 and BPV1 the DNA is shown in stick
representation in green. Note that for HPV16 both structures were determined
by NMR spectroscopy but there was no experimental determination of the
bound DNA conformation (hence no DNA is included in the model for the
complexed form). The a1 helix amino acids used for the overlays were as
listed in Table 3.
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Nonetheless, this needs to be treated with caution, as NMR
spectroscopy—based on local interactions—has limited
accuracy for the analysis of long-range changes of this
kind. However, a comparison of the unliganded HPV6 and
HPV16 E2 DBD crystal structures showed a displacement
of the DNA recognition helices by 7 A˚ (7), whereas in
this same study circular permutation assays indicated that
the DNA bend in the complexes that each of these proteins
forms with their cognate DNA sequences is highly similar.
HPV16 E2 DBD must therefore change to a similar confor-
mation to that reported here for HPV6 E2 DBD in order to
induce a similar bend in the DNA.
The effect of complex formation on the DNA structure
The DNA used for this study has a central AATT sequence,
sometimes referred to as an A-tract (4–6 consecutive adenine-
thymine residues). Solution studies and gel migration data
have indicated previously that A-tract sequences are charac-
teristically bent towards the minor groove (29). A crystallo-
graphic structure has been reported (17) for a dsDNA
dodecamer corresponding to the central sequence of the
16mer and 18mer used in this study. All copies of this
unliganded form of the E2 consensus sequence in the crystal
lattice displayed global curvatures of 8–10, with an unusu-
ally narrow minor groove (<4 A˚) at the A-tract core. In
contrast, dsDNA of sequence 50-ACCGACGTCGGT-30 or
50-ACCGGTACCGGT-30 has been shown by X-ray crystal-
lography to have either a straight or slightly bent conforma-
tion with no preference for the direction of the bend (30).
These degrees of curvature reported within crystal lattices
approximate to those measured using a lower-resolution but
solution-based method (31) and a predictive cyclization
kinetics method (32).
Assuming these conformations are representative of the
structures encountered within the cell, it is evident that
formation of a complex with the E2 DBD requires the
DNA to undergo significant further bending. Table 3 shows
the extent of this bending as observed in the three E2
DBD:DNA crystal complexes. On association with HPV6
E2, the target sequence is required to bend an additional
20, and the minor groove narrows further. This distortion,
however, is less than that observed for BPV1 E2 and HPV18
E2 (each with net bends of 30). The minor groove in the
latter is similarly closely spaced to the DNA in the current
study, implying a limit has been reached for narrowing of
the groove.
The predisposition of A-tracts to adopt a pre-bent structure
has been suggested to have entropic advantages promoting
formation of the E2 DBD:DNA complex (7,11). The asso-
ciated decrease in the width of the minor groove may also
create a more complementary docking surface for the E2
DNA recognition helices: the dodecamer 50-ACCGACGT-
CGGT-30, with a non-optimal spacer sequence, has an
increased minor groove width of 6 A˚ (Table 2). Both
HPV18 and (especially) HPV6 E2 proteins have significantly
reduced affinity for this sequence.
Surface electrostatic charges have been correlated freq-
uently with the capacity of proteins to bind to DNA, and
proposed to contribute to the ability of E2 DBD to promote
bending of DNA (2). HPV6 E2 DBD is a basic protein
with an overall pI value of 9.8. Calculating a pI for the
DNA recognition helices alone shows that HPV6 E2
DBD is less positive (pI ¼ 9.3) than HPV18 E2 DBD
(pI ¼ 11.0) or BPV1 E2 DBD (pI ¼ 10.5). This trend corre-
lates with an analysis of surface charge distribution of these
proteins (7) which indicated that the DNA-binding surfaces
of HPV18 and BPV1 E2 DBDs carry a higher density of
positive charge than either HPV6 or HPV16. An increase in
positive charge would be expected to enhance the electro-
static interaction between the DNA-binding helices and the
DNA backbone, and may therefore facilitate fitting of the
DNA to the protein recognition helices. The program
MadBend (33) was used to calculate the global bend angles
of various DNA sequences. The centre of the central spacer
was taken as a reference plane. The twist, roll and tilt angles
were calculated in FREEHELIX (34) and incorporated into
the MadBend angle calculation. Table 2 shows the results
of these calculations, which are broadly in agreement with
measurements of the bend angle observed in the crystal struc-
tures. From these data it can be seen that an increase in pI of
the recognition helices correlates with an increased global
bend angle.
Structural rearrangements of E2 DBDs on DNA
binding: solution studies
Comparisons of the available crystal structures of unliganded
and DNA-complexed E2 proteins indicate that structural
rearrangements of E2 DBD protein accompany DNA binding
(10,11). This has been further validated in solution studies of
HPV16 E2 DBD (15) and by monitoring fluorescence of pro-
tein tryptophan residues and an incorporated label on the
DNA (26). This latter study indicated the interaction of the
high-risk HPV16 E2 DBD with cognate DNA could be sepa-
rated into two phases: (i) a faster (k ¼ 8 s1) non-specific
association that is diffusion-controlled and appears to corre-
spond to encounter complex formation, and (ii) a slower
(k ¼ 0.04 s1) phase that does not depend on protein concen-
tration, is characterized by a decrease in fluorescence, and
has been interpreted as resulting from a substantial change
in the conformation of the protein after formation of the
DNA complex. This latter phase is also accompanied by a
slow enthalpic solvent exclusion step, to form the tightly
associated protein–DNA complex. These data are consistent
with the expectation, drawn from the crystallographic studies
of HPV18 E2 DBD, that HPV16 E2 DBD must also undergo
substantial rearrangement on complex formation. Because of
the close structural similarity of the HPV6 E2 DBD unli-
ganded and complexed forms, we applied a similar solution-
based fluorescence analysis (although limited to intrinsic
tryptophan fluorescence only) to both HPV6 and HPV16 E2
DBDs to explore whether a distinctive two-phase association
was also observed for the low-risk viral protein.
Representative data and derived rate constants are shown
in Figure 5 and Table 4, respectively. Under the conditions
studied, both HPV6 and HPV16 E2 DBDs showed a typical
increase in overall amplitude of fluorescence with an increase
in DNA concentration, as has been noted previously for
HPV16 E2 (24). The association curves for DNA binding
could readily be dissected into fast and slow components
by fitting to a double exponential rate equation, and the
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rates obtained were plotted against the DNA concentration
(Figure 5). The slow component is characterized by a
decrease in tryptophan fluorescence, consistent with a
molecular rearrangement event. For both proteins, the fast
rate is seen to increase linearly with increasing concentrations
of DNA, whereas the slow rate remains approximately
constant. We have interpreted these data according to a
two-step model for E2:DNA association in which there is
(i) a fast step representing the formation of the initial
E2:DNA complex and (ii) a subsequent, slower step correla-
ting with a molecular rearrangement of the protein to form a
tight-binding complex. This model is summarized in
Figure 6. For both HPV6 and HPV16 E2, the initial protein–
DNA complex is loosely associated with a dissociation
constant of 0.5 mM. We note that the on-rate is about
twice as fast for HPV16 E2; however, the off-rate is similarly
elevated. These differences might be explained by the differ-
ing electrostatics of the presenting surfaces of the respective
proteins, as discussed above. Both protein–DNA initial
complexes then undergo a slower rearrangement step, likely
to include both the molecular adaptation of the DNA-binding
helices as illustrated in the crystal structures, and expulsion of
solvent from the interface as proposed previously (24). The
final tight-binding complex achieved is of similar affinity
(2 nM) for both HPV6 and HPV16 E2 (7). However, the
molecular rearrangement step proceeds at different rates.
The forward rate is approximately twice as fast (30 s1) for
HPV6 E2 than for HPV16 E2 (16 s1). This is consistent
with a lower energetic barrier (DG) for molecular rearrange-
ment in the HPV6 E2:DNA complex, correlating with the
closer structural similarity of the unliganded and complexed
crystal structures of this protein.
The rate constants derived for HPV16 E2 DBD in this
study differ from those reported previously (26), although
this is not surprising as the solution conditions and methods
differ between these two studies. This previous study also
supported a two-step model for E2:DNA association.
However, their more detailed analysis obtained through the
stronger signal from the label incorporated within the DNA
permitted further dissection of the slow step.
HPV6 E2 DBD exhibits reduced deformability relative
to high-risk E2 DBDs
In combination, these data confirm that the association of
HPV6 E2 DBD with its cognate DNA—like HPV18,
HPV16 and BPV1 E2 DBDs—is characterized by a
multi-step procedure encompassing complex formation,
DNA-bending and conformational rearrangement of the
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Figure 5. Stopped-flow fluorescence data for the binding of (a) HPV6 E2 DBD and (b) HPV16 E2 DBD to the DNA sequence. Changes in the amplitude of
fluorescence measured at 340 nm were measured on the addition of aliquots of DNA to produce association curves for DNA binding, which were then fitted to a
double exponential rate equation to dissect the fast and slow components (lower graphs). The rates obtained were then plotted against the DNA concentration
(upper graphs).
Table 4. Kinetic data for E2:DNA complex formation obtained from stopped-
flow fluorescence experiments
Fast rate Slow rate
k1on (M
1 s1) k1off (s
1) k2on (s
1)
HPV6 E2 (9.2 ± 0.8) · 107 68 ± 16 29 ± 6
HPV16 E2 (2.63 ± 1.4) · 108 119 ± 14 16 ± 5
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DNA-binding helices of the protein. However, the crystallo-
graphic studies in particular support a model for HPV6 E2
DBD binding in which the protein has reduced deformability
relative to the equivalent domains from BPV1, HPV18 and—
most likely—HPV16. Firstly, the crystal structures indicate
that domain rearrangements for HPV6 E2 are minimal
(Figure 4 and Table 3) on complex formation. In contrast,
much larger changes in the protein conformation are evident
for both HPV18 and for HPV16—both from high-risk HPV.
BPV1 exhibits more segmental flexibility than HPV6 E2, but
less than seen in the HPV18 and HPV16 E2 structures. These
changes are mirrored in the degree of DNA bending evident
in the available crystal structures, where HPV6 E2 gives rise
to the smallest structural change within the DNA. Overall, the
interaction of HPV6 E2 with its DNA target is closer to the
traditional ‘lock and key’ mode of molecular recognition
than has been indicated for other E2 DBDs.
This model correlates with functional differences that have
been reported previously to distinguish HPV6 E2 from its
high-risk counterparts. Although E2 DBDs from HPV6 and
HPV16 bind their cognate DNA sequences with similar affin-
ity, HPV6 E2 is exquisitely sensitive to changes in the spacer
sequence. Altering the spacer from AATT to ACGT or
CCGG reduced binding of HPV16 E2 by about an order of
magnitude, but by greater than three orders of magnitude
for HPV6 E2 (7). As these latter sequences are known not
to induce the preferred ‘pre-bent’ DNA conformation with
narrowed minor groove approaching the conformation
observed within the E2:DNA complexes, it appears that bind-
ing will be increasingly compromised for HPV6 E2 where the
protein is less able to alter its own conformation to meet the
restrictions imposed by these altered targets.
We also note that the reduced adaptability of the HPV6 E2
DBD correlates with a stabilized b2–b3 loop in this protein.
In all other unliganded structures of HPV E2 proteins, this
loop is disordered, and it remains so in the HPV18
E2:DNA complex. The BPV1 E2:DNA complex shows an
ordered loop that interacts indirectly with the central spacer
of the DNA sequence. This interaction is believed to stabilize
the b2–b3 loop and reduce the electrostatic repulsion within
the compressed minor groove. Mutagenesis data for HPV16
E2 also suggest loop residues from this protein make contacts
to the DNA (26). However, in all structures of HPV6 E2
DBD, this loop is at least partially ordered, and no direct con-
tacts to the DNA are observed. In HPV6 E2, the b2–b3 loop
is shorter than in HPV18 E2, and is likely to be stabilized by
the presence of two proline residues (Pro322 and Pro325) and
additionally possibly through the formation of a salt bridge
between Lys323 in the loop and Asp311 from the other mole-
cule in the dimer. In the HPV6 E2:DNA complex, the loop
remains in the same conformation, positioned such that no
contact is made between loop residues and the DNA.
Although it seems unlikely that this loop would have an
effect on the stable central b-barrel structure, it is possible
that its presence across the centre of the dimer might impose
a restriction on the degree of movement accessible to the
nearby a1 recognition helix.
Previous solution-based (NMR) studies of E2 DBDs have
indicated that, although the a1 recognition helix is consis-
tently well defined with average backbone r.m.s.d. values in
all structures determined, most amide groups from this region
exchange relatively quickly with solvent (12,13,15). This is
believed to indicate that the helix is comparatively flexible
within the E2 DBD. However, the high correlation in its
placement when the six independent copies of the dimer
from the two different apo HPV6 E2 structures are compared
implies that the observed position reflects a genuinely pre-
ferred minimum energy conformation. Recent studies indi-
cate that at least 90% of the binding energy between E2
DBD and its DNA arises from additive direct and water-
mediated interactions between the protein and DNA (26).
The adaptation of the helix positioning from a preferred
location as observed in the apo structures to its bound con-
formation is consistent with this model. Although the helix
may indeed need to sample a range of conformations in
order to effect binding of its ligand, the closer proximity of
the favoured bound conformation for HPV6 E2 implies
this position could be more readily reached, as reflected in
the kinetic data.
Biological implications of reduced flexibility
in HPV6 E2
HPV E2 proteins are known to differ substantially in their
ability to activate transcription, with E2 proteins from
‘high-risk’ papillomaviruses generally proving more potent
activators (35,36). These differences might be attributable
to differences in the E2 trans-activation domains, or could
also reflect changes in the association of E2 subtypes with
the viral DNA. There are four E2-binding sites in the HPV
LCR, each at conserved positions relative to the transcription
start point. It has been noted previously that there is a clear
hierarchy in the occupation of these sites that distinguishes
the high-risk HPV16 E2 protein from low-risk HPV6 E2
(7). Specifically, greater variation was observed in the bind-
ing of HPV6 E2 to the four sites than was found for
Figure 6. Proposed model for DNA complex formation for E2 proteins. In
each case the E2 protein is abbreviated as E and the DNA as D. E:D
represents the initial weakly associated complex, and E*:D the tight complex
formed after molecular rearrangement of the protein.
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HPV16 E2 protein. These sites are most readily distinguished
through the differing composition of their A-tract spacer
sequences, which in turn implies differing propensities for
forming pre-bent structures. The limited deformability of
the HPV6 E2 DBD noted in the current study provides a
molecular explanation for the reduced tolerance for spacer
variation observed for this low-risk HPV protein. This higher
level of selectivity in binding the viral genome may correlate
with diminished ability to activate transcription.
Atomic coordinates
The coordinates and structure factors for E2 DBD–18mer, E2
DBD–16mer and E2 DBD-S have been deposited in the
Protein Data Bank under the accession codes 2AYG, 2AYB
and 2AYE, respectively.
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